Anumana Inc.

Anumana Inc. is a cardiovascular AI software company headquartered in Cambridge, MA, developing FDA-cleared algorithms for ECG analysis and cardiac disease detection. Founded in 2021 as a joint effort between Mayo Clinic and nference, the company specializes in ECG-AI®, a proprietary platform that analyzes 12-lead electrocardiograms using deep learning to identify cardiac pathology invisible to clinicians. The flagship algorithm detects low ejection fraction (LEF) and is clinically validated on approximately 2.9 million ECG-echo pairs from 676,000+ patients across diverse populations. The platform has received FDA 510(k) clearance (K250652) for LEF detection and recent clearances for cardiac amyloidosis and pulmonary hypertension algorithms. Anumana's technology integrates seamlessly into existing EHR systems and ECG management platforms without requiring external data processing—algorithms run on-premises for enhanced data security and privacy. The company's AI engine processes 60,000 ECG data points per study and delivers clinical findings compatible with current cardiology workflow. Product portfolio includes multiple cardiac-focused algorithms in development spanning early disease detection, perioperative imaging, atrial fibrillation risk stratification, hyperkalemia detection, diastolic dysfunction assessment, and cardiomyopathy screening. Clinical evidence published across 100+ peer-reviewed publications in journals including Nature Medicine, JACC, and European Heart Journal. The platform supports EHR orderable creation, HL7 configuration, CPT code assignment, and is eligible for reimbursement in US and EU markets. Anumana serves cardiology practices, hospitals, and integrated health systems seeking AI-assisted ECG interpretation and early identification of at-risk cardiac patients.